Interventional treatment of obesity and diabetes: An interim report on gastric electrical stimulation.
Gastric electrical stimulation has been applied to treat human obesity since 1995. Dilatation of the stomach causes a series of neural reflexes which result in satiation and satiety. In non-obese individuals food ingestion is limited in part by this mechanism. In obese individuals, satiation and satiety are defective and unable to limit energy intake and prevent excessive weight gain. Several gastric electrical stimulatory (GES) devices have been developed, tested in clinical trials and even approved for the treatment of obesity. The design and clinical utility of three devices (Transend®, Maestro® and DIAMOND®) that have been extensively studied are presented as well as that of a new device (abiliti®) which is in early development. The Transcend®, a low energy GES device, showed promising results in open label studies but failed to show a difference from placebo in decreasing weight in obese subjects. The results of the clinical trials in treating obese subjects with the Maestro®, a vagal nerve stimulator, were sufficient to gain approval for marketing the device. The DIAMOND®, a multi-electrode GES device, has been used to treat type 2 diabetes and an associated benefit is to reduce body weight and lower systolic blood pressure.
State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Box 1205, Brooklyn, New York, 11203, USA. hlebovitz1@hotmail.com.
Harold E
HE
Lebovitz
D003920:Diabetes Mellitus / Q000628:therapy*; D004599:Electric Stimulation Therapy / Q000295:instrumentation / Q000379:methods; D006801:Humans; D009765:Obesity / Q000628:therapy*; D013270:Stomach / Q000294:innervation*; D055536:Vagus Nerve Stimulation / Q000295:instrumentation / Q000379:methods
Gastric electrical stimulation; Glycemic control; Obesity; Type 2 diabetes; Weight loss